Mylan's acquisition of Meda was completed on August 5, 2016. Learn more.
Meda has a well-diversified product portfolio, a global presence, and is represented within all areas of pharmaceuticals: Specialty Products, Cx, and OTC
CB12 is a powerful, unique and patented mouth rinse that ensures not only first class breath, but also provides a daily shot of confidence. Every day and all day CB12 provides 12 hours of protection.
EndWarts is an effective treatment for self-removal of warts on hands, feet and the body.
Dymista is a new nasal spray for the treatment of allergic rhinitis. Dymista is a novel formulation of Azelastine and fluticasone propionate.
Zyclara is an immune response modulator agent, Imiquimod 3,75%, for the treatment of large areas of actinic keratosis.
Elidel is a steroid free drug, Pimecrolimus, for the treatment of atopic dermatitis, which is a chronic recurring inflammatory skin disease.
This website is intended for people seeking information on Meda AB's Global operations. We also have national marketing sites. Links to these are under Meda Worldwide at the top of the page.